Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Summary

The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.

Timeline

Start

2020-11-19

Primary completion

2023-10-30

Completion

2024-08-19

Publications

• Wolf S, Chen Y, Li X, Shimura M, Sakamoto T, Wykoff CC, Emanuelli A, Salehi-Had H, Yan K, Kovacic L, Kim Y. Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial. JAMA Ophthalmol. 2026 Jun 1;144(6):500-507. doi: 10.1001/jamaophthalmol.2026.1008.

Drugs

Indications